New long-term clinical data presented by Eisai add to growing evidence that LEQEMBI (lecanemab) may continue to slow disease progression in certain adults with early Alzheimer’s disease when treatment is maintained over several years. …
New long-term data suggest sustained benefit of Eisai therapy in early Alzheimer’s Disease
January 30, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News